Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001981282 | SCV002284002 | uncertain significance | not provided | 2023-09-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 1492849). This variant has not been reported in the literature in individuals affected with FSCN2-related conditions. This variant is present in population databases (rs782333124, gnomAD 0.07%), and has an allele count higher than expected for a pathogenic variant. This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 225 of the FSCN2 protein (p.Asp225Tyr). |
Dept Of Ophthalmology, |
RCV003888980 | SCV004706254 | benign | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Ambry Genetics | RCV004045380 | SCV004876141 | uncertain significance | not specified | 2023-12-15 | criteria provided, single submitter | clinical testing | The c.673G>T (p.D225Y) alteration is located in exon 1 (coding exon 1) of the FSCN2 gene. This alteration results from a G to T substitution at nucleotide position 673, causing the aspartic acid (D) at amino acid position 225 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |